secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001193125-23-267745
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated
--------------------------------------------------------------------------------

- Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.
- Prior $300M ATM with Jefferies terminated; no shares had been sold under that agreement.
- Cowen will receive up to 3.0% commission on gross proceeds from sales.
- ATM offering made under existing shelf registration statement (File No. 333-269899).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/0001193125-23-267745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312523267745/d282676d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-267745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer